Real Money authors - Bret Jensen

Bret Jensen

With over 20 years of experience in the financial industry, Bret Jensen brings success as an investor and entrepreneur to TheStreet Real Money Pro team. As the chief investment strategist at Simplified Asset Management between 2008-2011, Jensen’s small long/short hedge fund was in the top 5% of long/short hedge funds for total return in its first full year (2009) as ranked by Hedgeco fund database. He currently acts as corporate secretary for Florida Alternative Investment Association, which encompasses more than 100 managers managing more than $30 billion in assets under management. 

Jensen specializes in value and GARP investing, along with simple options strategies like covered call trades. He is passionate about teaching others how to achieve financial independence at a relatively young age like he did. 

He has been a Real Money and Real Money Pro contributor for TheStreet team since 2012. His coverage focuses primarily on sector coverage, stock trading ideas, options trading, and macroeconomic trends. Fun fact about Jensen: he became a professional poker player at the age of 18 before turning his attention to investing. 

Email Bret Jensen

Recent Articles By The Author

I See Some Money in This 'ATM' Play

Here's a strategy for NCR Corporation after its split up.

Free Cash Flow Is Key to Business Survival, and It's Why I Like These 2 Stocks

A logistics giant and a small biotech have seen their shares struggle this year, but they are producing solid cash flow and look undervalued.

2 Notable Stocks Insiders Are Buying in a Miserable Market

Looking for trading ideas? Company insiders are voicing their confidence in these names.

The Risk of Another Huge Fed Policy Mistake Is Running High

This time, the misstep is related to reading the impact on employment that the Fed's aggressive rate hikes already have had on the job market.

With My Lantheus Trade, 'If It Ain't Broke, Don't Fix It'

Here's a covered a call idea follow-up from June.

Here's What to Expect From Biotech in 2023

After a cruel 2022, here are my views on this high-beta sector as we head into the new year.

Investors Should Prepare for a Rough Start to 2023

Wednesday's poor ADP Jobs Report portends things to come.

Here Are 2 Value Plays to Consider

If one looks hard enough there are still some reasonable values to be had.

This Biopharma 'Fits the Bill' as a Growth Play

These kind of names are in short supply in the current market.

At the Closing Bell

Good chatting with everyone on the Daily Diary today. Not a whole lot of market action to talk about this Friday, as the indexes moved little from their initial moves after the opening bell. In the wait and see story of the day outside the U.S., the...

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight